Skin-Adhered Pump Pods
The pump, reservoir and cannula sit directly on the body, reducing tubing and allowing discreet wear under clothing.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Basal Insulin, Bolus Insulin, Basal-Bolus Insulin), By Application (Hospital, Clinic, Others), By Diabetes Type (Type 1 Diabetes, Type 2 Diabetes, Other Insulin-Requiring Diabetes), By Technology (Standard Tubeless Patch Pumps, Connected / Smart Patch Pumps, Automated Insulin Delivery Patch Pumps), By Distribution Channel (Hospital / Diabetes Centers, Medical Device & Pharmacy Channels, Online / Direct Supply), and Regional Forecast, 2026-2034
The global wearable insulin patch pump market was valued at USD 1.32 billion in 2025 and is estimated at USD 1.45 billion in 2026. The market is projected to reach USD 3.08 billion by 2034, representing a 9.9% CAGR during 2026–2034.
Wearable insulin patch pumps are compact, body-worn insulin delivery devices that attach directly to the skin and remove the long external tubing used by conventional pumps. The category includes patch systems designed for basal delivery, bolus delivery and combined basal-bolus therapy, with increasing integration of continuous glucose monitoring, smartphone control and automated insulin delivery algorithms.
The addressable diabetes population continues to expand. The International Diabetes Federation reported 589 million adults aged 20–79 living with diabetes in 2024 and projects 853 million by 2050. IDF also estimates 9.1 million people living with type 1 diabetes, creating a large long-term population for intensive insulin delivery technologies.
Regulatory and product development are broadening patch-pump use beyond traditional type 1 diabetes. FDA expanded Insulet SmartAdjust automated insulin dosing to adults with type 2 diabetes in August 2024 after the SECURE-T2D study enrolled 343 adults. In 2026, Insulet rolled out an enhanced Omnipod 5 algorithm and FreeStyle Libre 3 Plus compatibility, while Medtrum advanced a 300-unit tubeless patch pump toward German launch and Tandem continued development of next-generation patch-pump platforms.
Source: IDF Diabetes Atlas; FDA Type 2 AID clearance; FDA SECURE-T2D review; Insulet 2026 Omnipod 5 update; Medtrum 300U patch pump.
The study defines the global wearable insulin patch pump market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Basal Insulin; Bolus Insulin; Basal-Bolus Insulin |
| By Application | Hospital; Clinic; Others |
| By Diabetes Type | Type 1 Diabetes; Type 2 Diabetes; Other Insulin-Requiring Diabetes |
| By Technology | Standard Tubeless Patch Pumps; Connected / Smart Patch Pumps; Automated Insulin Delivery Patch Pumps |
| By Distribution Channel | Hospital / Diabetes Centers; Medical Device & Pharmacy Channels; Online / Direct Supply |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Netherlands; China; Japan; South Korea; India; Australia; Brazil; Mexico and other relevant markets |
| Key Market Players | Insulet Corporation; Medtrum Technologies; Tandem Diabetes Care; EOFlow; CeQur; Terumo Corporation; MicroTech Medical; PharmaSens; Modular Medical; Medtronic |
The market includes wearable, skin-adhered insulin pumps designed to deliver insulin without long external tubing. Revenue covers commercially available and defined patch-pump systems used for basal, bolus or basal-bolus insulin delivery and closely associated controllers where they are integral to the pump platform.
Conventional tethered insulin pumps, standalone continuous glucose monitors, insulin pens and smart pens are outside the core revenue boundary unless discussed as competing or integrated technologies. Pipeline patch pumps are discussed in the technology and competitive sections but are not treated as commercial revenue before market entry.
IDF estimates 589 million adults were living with diabetes in 2024 and projects 853 million by 2050. Even a modest increase in pump-eligible penetration creates substantial device and recurring pod demand.
FDA’s 2024 expansion of SmartAdjust to adults with type 2 diabetes was the first clearance enabling automated insulin dosing for this population. This opens patch-pump automation to a much larger insulin-using group than the traditional type 1 market.
Omnipod 5 now supports multiple leading CGM options in the United States, and Medtrum integrates its patch pump with the Nano CGM and APGO algorithm. Competitive differentiation increasingly depends on sensor choice and interoperability rather than pump hardware alone.
Many patch pumps historically used reservoirs near 200 units, which can require more frequent changes for people with higher insulin needs. Medtrum’s 300-unit design adds 50% more capacity than a 200-unit reservoir while retaining a tubeless format.
Patch pumps can be supplied through pharmacy or durable-medical-equipment pathways depending on product and market. Coverage, co-pay structure and regional reimbursement determine whether convenience advantages translate into sustained adoption.
Source: IDF; FDA Type 2 clearance; Insulet 2026; Medtrum 300U.
Patch pumps increasingly integrate CGM data and control algorithms to adjust insulin automatically. Omnipod 5 and Medtrum TouchCare show how the category is moving from simple tubeless infusion toward software-defined therapy.
Insulet’s June 2026 U.S. rollout added FreeStyle Libre 3 Plus compatibility alongside existing sensor options. Broader CGM choice can reduce switching friction and make patch-pump adoption more attractive to established sensor users.
Medtrum’s 300-unit pump is designed for users with greater daily insulin requirements and has entered reimbursement pathways in Germany. Capacity expansion directly addresses a constraint that can limit patch-pump practicality for type 2 diabetes.
Tandem states that its pipeline includes a tubeless extended-wear Mobi configuration and a next-generation patch pump using technology acquired with the Sigi platform. This adds competitive pressure from established automated-insulin-delivery companies.
Medtrum presented 2026 data on Auto Meal Handling, allowing users to announce meal type rather than perform full carbohydrate calculations. Reducing user input is an important step toward lower-burden closed-loop therapy.
Source: Insulet 2026 algorithm; Medtrum 300U; Tandem innovations; Medtrum ATTD 2026.
Wearable patch pumps combine miniaturized pumping, reservoirs, insertion mechanisms, wireless control and increasingly CGM-driven algorithms. Competitive advantage depends on reliable insulin delivery, body-worn comfort and software integration.
The pump, reservoir and cannula sit directly on the body, reducing tubing and allowing discreet wear under clothing.
Bluetooth or proprietary wireless control enables bolus delivery, settings management and data review without direct interaction with the patch.
AID systems use glucose data to adjust insulin delivery and reduce manual therapy burden while maintaining user safety controls.
Reservoir volume, battery life, adhesive performance and multi-day wear determine how often users must replace or interact with the device.
Source: FDA Type 2 clearance; Medtrum Nano Pump; Tandem innovations.
By type, the market is segmented into basal insulin, bolus insulin and basal-bolus insulin patch pumps. Basal-bolus systems are the leading value segment because they can support comprehensive intensive insulin therapy in one wearable platform.
Basal-focused patch systems provide continuous background insulin and target users who need simplified delivery without full automated meal dosing. They can be particularly relevant for insulin-requiring type 2 diabetes.
Bolus-focused systems provide discreet on-demand mealtime or correction insulin and can replace repeated injections for users who do not require continuous basal pump therapy.
Basal-bolus systems deliver continuous background insulin and programmable mealtime doses. This format provides the strongest platform for CGM-integrated automated insulin delivery.
Basal-bolus systems are expected to retain the highest technology value, while basal-only and bolus-focused patches can broaden adoption among users seeking simpler alternatives to full pump therapy.
By application, the market is segmented into hospitals, clinics and other care settings. Clinics and diabetes centers are central to device selection and training, while most ongoing pump use occurs in daily life outside institutional settings.
Hospitals initiate pump therapy for complex diabetes cases, inpatient transitions and specialist assessment, particularly where multidisciplinary diabetes programs are available.
Endocrinology and diabetes clinics are the primary setting for pump selection, training, CGM integration and follow-up. Their recommendation strongly influences device adoption.
After initiation, patch pumps are primarily worn and managed at home, work, school and other community settings, making usability and remote support essential to long-term adherence.
Clinics will remain the most influential professional channel for pump initiation, while the value proposition is ultimately determined by reliable, low-burden daily use outside the clinic.
By diabetes type, the market is segmented into type 1 diabetes, type 2 diabetes and other insulin-requiring diabetes. Type 1 diabetes remains the established pump base, while insulin-treated type 2 diabetes is the largest expansion opportunity.
People with type 1 diabetes require lifelong insulin and have historically driven adoption of continuous subcutaneous insulin infusion and automated delivery systems.
FDA clearance of automated insulin dosing for adults with type 2 diabetes creates a major growth pathway, particularly for users requiring intensive daily insulin but seeking a simpler delivery experience.
Other use includes selected pancreatic, post-surgical or secondary diabetes cases where continuous insulin delivery may be clinically appropriate.
Type 1 diabetes will remain the established revenue base, while type 2 diabetes should contribute a rising share of incremental growth as device indications and reimbursement broaden.
By technology, the market is segmented into standard tubeless patch pumps, connected or smart patch pumps, and automated insulin delivery patch pumps. Automated systems are the fastest-moving segment because software and CGM integration increase clinical value.
Standard systems focus on discreet, tubing-free insulin delivery and may use a dedicated controller without continuous algorithm-based glucose adjustment.
Smart pumps add mobile control, cloud data and remote sharing, improving convenience and enabling integration with broader diabetes-management platforms.
AID systems combine a patch pump, CGM and dosing algorithm to adjust insulin automatically. Algorithm performance and sensor interoperability are becoming central competitive factors.
Automated patch pumps are expected to capture an increasing share of market value, while standard and connected devices remain important where affordability, simplicity or regional regulatory access limit full automation.
By distribution channel, the market is segmented into hospital or diabetes-center supply, medical-device and pharmacy channels, and online or direct supply. The mix varies significantly by reimbursement system and country.
Specialist centers support device starts, education and payer documentation and can directly coordinate pump access in institution-led healthcare systems.
Distributors, specialty pharmacies and durable-medical-equipment suppliers handle much of the recurring pump and pod fulfillment in mature markets.
Manufacturer-direct and digital ordering can simplify recurring consumable replenishment and support users in markets where remote diabetes care is established.
Medical-device and pharmacy channels will remain central to reimbursement-linked supply, while direct digital fulfillment can improve recurring pod access and customer retention.
Regional adoption follows reimbursement, CGM penetration, specialist diabetes care and regulatory access. North America is the largest market, while Europe has strong patch-pump competition and Asia-Pacific offers the largest long-term patient-volume opportunity.
North America leads through early Omnipod adoption, broad CGM use, advanced diabetes clinics and expanding automated insulin delivery coverage.
Europe supports Insulet, Medtrum and other patch-pump platforms across national reimbursement systems, with Germany, France, the Netherlands and the United Kingdom representing key markets.
The region contains major diabetes populations and growing local device manufacturing. Adoption is strongest where reimbursement and specialist access support advanced pump therapy.
Adoption is growing in private and insured diabetes-care segments, but device cost and recurring consumable coverage remain major barriers.
Gulf markets support premium diabetes technology, while broader regional penetration is constrained by reimbursement and specialist access. Insulet reported Omnipod 5 availability in five Middle East countries by Q1 2026.
Source: IDF Atlas; Insulet Q1 2026; Medtrum Germany.
Wearable insulin patch pumps are safety-critical infusion devices and, when automated, combine pump hardware with glucose sensors and dosing software. Regulatory review therefore covers delivery accuracy, interoperability, algorithm performance, human factors and cybersecurity.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Type 2 automated dosing expansion | FDA expanded Insulet SmartAdjust to adults with type 2 diabetes in August 2024. | Broadens the eligible U.S. population for automated patch-pump therapy. |
| Algorithm lifecycle regulation | FDA cleared an updated Omnipod 5 algorithm under K251779 in December 2025. | Shows that software improvements require ongoing regulated lifecycle management. |
| Clinical evidence | SECURE-T2D enrolled 343 adults and included a 13-week Omnipod 5 treatment phase after baseline therapy. | Provides direct evidence supporting type 2 expansion. |
| Reimbursement pathways | Patch-pump coverage can run through pharmacy, device or national health-insurance channels. | Makes payer access and coding a major competitive factor alongside device performance. |
Source: FDA Type 2 clearance; FDA K241777; FDA algorithm clearance; Medtrum Germany.
Competition is intensifying as established tubeless leaders, European patch-pump specialists and conventional pump companies converge on automated body-worn delivery. Differentiation centers on algorithm quality, sensor choice, reservoir capacity, device size, wear time, smartphone control, reimbursement and recurring consumable economics.
Omnipod 5 combines a disposable patch pump with automated insulin delivery and has expanded CGM compatibility and geographic reach through 2026.
Medtrum offers 200U and 300U tubeless pumps integrated with CGM and its APGO algorithm, with active European expansion.
Tandem is developing a tubeless Mobi configuration and a next-generation patch pump using technology from the Sigi platform acquired with AMF Medical.
Specialists compete across disposable, reusable, simplified bolus and automated patch-pump concepts, increasing technology and pricing diversity.
Source: Insulet 2026; Medtrum products; Tandem innovations.
August 2026: Tandem Diabetes Care updated its product-development roadmap to include a tubeless extended-wear Mobi configuration and a next-generation patch pump leveraging Sigi technology acquired with AMF Medical.
July 2026: Medtrum advanced its 300-unit tubeless patch pump toward German commercial launch after DDG 2026 presentation and listing in Germany’s statutory health-insurance medical-aids directory.
June 2026: Insulet began U.S. rollout of an enhanced Omnipod 5 algorithm and added compatibility with Abbott’s FreeStyle Libre 3 Plus sensor following FDA clearance.
April 2026: Medtrum presented six-month ATTD data on Auto Meal Handling within its AID system, supporting development toward lower-burden closed-loop insulin delivery.
Source: Tandem innovations; Medtrum 300U; Insulet 2026; Medtrum ATTD.
The global wearable insulin patch pump market market is projected to grow from USD 1.45 billion in 2026 to USD 3.08 billion by 2034, at a 9.9% CAGR during 2026–2034. Growth is expected to be supported by broader pump adoption, type 2 diabetes indications, CGM interoperability and automated insulin delivery. The strongest commercial platforms will combine discreet wearability with reliable algorithms, strong reimbursement, sensor choice and efficient recurring consumable supply.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Diabetes prevalence | IDF reports 589 million adults with diabetes. | Creates a growing addressable population for insulin technology. |
| Type 2 expansion | FDA cleared automated dosing for adults with type 2 diabetes. | Opens a major new patch-pump user group. |
| CGM interoperability | Leading systems support multiple sensor options. | Reduces switching friction and strengthens platform value. |
| Higher-capacity devices | 300U designs target users with greater insulin requirements. | Improves suitability for insulin-intensive type 2 diabetes. |
| Competitive pipeline | Tandem and other established pump companies are developing patch formats. | Increases innovation and commercial competition. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global wearable insulin patch pump market landscape.
24LifeScience develops wearable insulin patch pump market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current IDF diabetes-burden data, FDA device decisions and primary manufacturer disclosures on commercially available and pipeline patch-pump systems. Commercial revenue is limited to wearable insulin patch-pump platforms, while pipeline products are discussed as competitive and technology developments rather than current sales.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 1.32 billion in 2025 and is estimated at USD 1.45 billion in 2026. It is projected to reach USD 3.08 billion by 2034 at a 9.9% CAGR during 2026–2034.
It is a body-worn insulin pump that adheres directly to the skin and delivers insulin without the long external tubing used by conventional pumps.
North America is the largest regional market because of strong reimbursement, CGM adoption, specialist diabetes care and early access to automated tubeless insulin delivery.
Basal-bolus patch pumps are the leading value segment because they can provide both background and mealtime insulin and support automated insulin delivery.
FDA expanded automated insulin dosing with Insulet SmartAdjust to adults with type 2 diabetes, opening a much larger insulin-using population to patch-pump therapy.
CGM integration enables automated insulin adjustment and allows pump companies to compete on algorithm performance, sensor choice and time-in-range outcomes.
Cost, reimbursement, adhesive performance, reservoir capacity, training and the recurring cost of disposable pods can limit adoption.
The report profiles Insulet, Medtrum, Tandem Diabetes Care, EOFlow, CeQur, Terumo, MicroTech Medical, PharmaSens, Modular Medical and Medtronic.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.